Glass House Brands (GLAS) Assets Average (2021 - 2026)
Glass House Brands' (GLAS) quarterly Assets Average came in at $322.0 million in Q1 2026, up 3.51% year-on-year from $311.0 million in Q1 2025, and up 0.87% on a QoQ basis from $319.2 million in Q4 2025.
Glass House Brands (GLAS) Assets Average (2021 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 6 years of Assets Average data on file, last reported at $322.0 million in Q1 2026.
- On a quarterly basis, Assets Average rose 3.51% year-over-year to $322.0 million in Q1 2026; TTM through Mar 2026 was $322.0 million, a 3.51% increase from a year earlier, with the FY2025 full-year figure at $314.5 million, up 2.41% from the prior year.
- Assets Average for Q1 2026 stood at $322.0 million, up from $319.2 million in the prior quarter.
- Over the last five years, Assets Average for GLAS reached as high as $350.1 million in Q4 2022 and fell as low as $139.4 million in Q1 2022.
- Historically, Assets Average has averaged $308.8 million across 5 years, with a median of $322.0 million in 2026.
- On a YoY basis, Assets Average climbed as much as 164.95% in 2022 and fell as far as 80.56% in 2022.
- Year by year, Assets Average stood at $350.1 million in 2022, then slipped by 7.83% to $322.7 million in 2023, then fell by 3.43% to $311.6 million in 2024, then rose by 2.43% to $319.2 million in 2025, then advanced by 0.87% to $322.0 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $322.0 million in Q1 2026, $319.2 million in Q4 2025, and $327.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 7.30 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 21.86 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 321.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 321.96 Mn |
| Dec 31, 2025 | 319.19 Mn |
| Sep 30, 2025 | 327.19 Mn |
| Jun 30, 2025 | 323.08 Mn |
| Mar 31, 2025 | 311.05 Mn |
| Dec 31, 2024 | 311.62 Mn |
| Sep 30, 2024 | 309.29 Mn |
| Jun 30, 2024 | 300.55 Mn |
| Mar 31, 2024 | 299.51 Mn |
| Dec 31, 2023 | 322.68 Mn |
| Sep 30, 2023 | 333.10 Mn |
| Jun 30, 2023 | 324.65 Mn |
| Mar 31, 2023 | 337.66 Mn |
| Dec 31, 2022 | 350.09 Mn |
| Sep 30, 2022 | 328.40 Mn |
| Jun 30, 2022 | 290.20 Mn |
| Mar 31, 2022 | 139.43 Mn |
| Dec 31, 2021 | 132.14 Mn |
| Sep 30, 2021 | 231.02 Mn |
| Jun 30, 2021 | 459.60 Mn |